May 2 Biotec Pharmacon Asa:
* UK Drug Tariff rejects current Woulgan application
* Subsidiary Biotec Betaglucan has received negative feedback from uk drug tariff regarding application for reimbursement
* management are considering if there are grounds for an appeal in line with NHS' own guidelines
* UK Drug Tariff informed co that nhs has decided not to list woulgan because they consider evidence provided to be insufficient to document cost effectiveness Source text for Eikon: Further company coverage:
UPDATE 1-Pan American Energy to invest $1.2 bln in Argentina in 2017
BUENOS AIRES, June 27 Argentina-based Pan American Energy, a unit of BP Plc, will invest some $1.2 billion in the South American country this year, a company spokesman said on Tuesday, down from the $1.4 billion that the company had announced for 2016.